You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The pediatric health system will use RPRD's pharmacogenomics testing platform in its cancer and blood disorder clinic and its neurology/psychology practice.
Metagenomic sequencing may be a good tool to improve the diagnostic rate because it is such a broad approach and does not require "guessing" at the potential pathogen.
Researchers identified Neanderthal alleles associated with human conditions using genotypic and phenotypic information in health records for more than 28,000 individuals.
The results showed that syndromic forms of autism are more likely when children have alterations of genes in the mGluR pathway.
The life sciences company can now offer its genetic tests in all 50 states in the US, as well as Canada and several other countries.
TwoXar will use the funds to expand its engineering and commercial teams and support partnerships focused on drug candidates for metabolic and neurological diseases.
The company's platform offers space and computational tools for exploring, sharing, and storing genomic data in the context of genetic disorders.
Amarantus will use the investment to develop and commercialize its neurology diagnostic products and drug candidates, and for other working capital expenses.
The test, called Neurome, is available from Athena, Quest Diagnostics' genetic testing business for neurological disorders, and is performed by Personalis.
Researchers also plan to launch a prospective randomized clinical trial to test the effectiveness of whole-genome sequencing compared to the standard of care.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.